Market Trends AstraZeneca’s Imfinzi gains additional indication for bladder cancerBy admin8996erT0allMarch 28, 2025 Wirestock The U.S. FDA has granted an additional indication for AstraZeneca’s (NASDAQ:AZN) Imfinzi (durvalumab) to include muscle invasive bladder cancer.…
Market Trends J&J boasts Rybrevant, Lazcluze combo bests AstraZeneca’s TagrissoBy admin8996erT0allMarch 26, 2025 yuelan Johnson & Johnson (NYSE:JNJ) said that data from a phase 3 trial indicated that a combination of Rybrevant (amivantamab)…
Market Trends AstraZeneca’s metastatic breast cancer treatment gets EU recommendation (AZN:NASDAQ)By admin8996erT0allFebruary 28, 2025 koto_fejaAstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said on Friday that the European Medicines Agency (EMA) endorsed ENHERTU for the treatment of…
Market Trends AstraZeneca’s Enhertu gets additional FDA approval (AZN:NASDAQ)By admin8996erT0allJanuary 27, 2025 WirestockAstraZeneca (NASDAQ:AZN) and Daiichi Sankyo’s (OTCPK:DSKYF) drug Enhertu has been approved by the FDA for the treatment of certain breast…
